Alkem Laboratories announced on Thursday that the US Food and Drug Administration had inspected its Taloja facility in Maharashtra and found “zero” issues.
From July 26-28, 2021, the US Food and Drug Administration (USFDA) conducted a remote and virtual bio-analytical inspection of Alkem Laboratories’ Bioequivalence Center in Taloja, Maharashtra, according to a regulatory filing.
At the end of the inspection, no form 483 was issued, the company added. A form 483 is issued by the USFDA to notify a company’s management of any objectionable condition at its manufacturing facility. The form is issued after completing the inspection.
Shares of Alkem Laboratories were trading 0.30 percent lower at Rs 3,362.05 apiece on BSE.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…